Skip to main content
U2BIO CO., LTD. logo

U2BIO CO., LTD. — Investor Relations & Filings

Ticker · 221800 ISIN · KR7221800006 KO Human health and social work activities
Open in API
Filings indexed 228 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country KR South Korea
Listing KO 221800

About U2BIO CO., LTD.

https://www.u2bio.co.kr/eng/main.do

U2BIO CO., LTD. is a healthcare technology company specializing in the integration of biotechnology (BT) and information technology (IT). The company provides a range of in vitro diagnostic services, including clinical laboratory tests and molecular diagnostics. Concurrently, it develops and offers digital healthcare solutions and medical IT services tailored for medical institutions such as hospitals and clinics. U2BIO focuses on delivering personalized healthcare services based on scientific data to support medical professionals and improve patient health outcomes.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory disclosure of an extraordinary shareholders’ meeting convocation (“주주총회소집결의”) including correction details and the full agenda. It is not presenting the contents of an annual report, proxy materials under US SEC forms, nor minutes/results. Instead, it is a standard regulatory announcement about convening a shareholders’ meeting and therefore falls under the general Regulatory Filings category (RNS).
2026-05-26 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 91% confidence The document is a Korean "주요사항보고서(유상증자결정) 정정신고" (Major Reports on paid-in capital increase decision, corrected report). It details a decision to issue new shares via third-party allotment, including issuance terms, pricing, use of proceeds, and regulatory basis. This is clearly an announcement of a new share issue/capital change. According to our taxonomy, announcements regarding new share issues or capital changes fall under Share Issue/Capital Change (SHA), not a general financing update or fallback. Therefore the correct classification is SHA.
2026-05-22 Korean
타법인주식및출자증권취득결정
Regulatory Filings Classification · 78% confidence The document is a Korean regulatory disclosure titled “Decision to Acquire Shares and Equity Securities of Another Corporation” (타법인 주식 및 출자증권 취득결정). It details the reporting company’s decision to subscribe for new shares in a third party via a third-party allotment, including share counts, amounts, dates, and board resolutions. This is not the company’s own share buyback (POS), nor an issuance by the reporting company (SHA), nor a merger/takeover (MA/TAR), nor an earnings release (ER). It also does not include full financial statements as in an interim report (IR) or annual report (10-K). It is a routine material event disclosure under exchange rules, with no standalone category more specific in our taxonomy. Therefore, it falls into the miscellaneous regulatory announcement category (RNS).
2026-05-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 93% confidence The document is a standard Korean large shareholding status report (“주식등의 대량보유상황보고서”) filed under the Capital Markets Act, detailing the number of shares and percent holdings before and after changes, listing major shareholders and related-party movements. This is a notification of changes in significant share ownership levels, fitting the Major Shareholding Notification category.
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 87% confidence The document is a Korean ‘공정공시’ (fair disclosure) of provisional Q1 2026 consolidated operating results. It provides key headline metrics (sales, operating profit, net profit) for the quarter, compares to prior periods, and announces an IR conference call. This matches an initial earnings announcement (quarterly results) rather than a full interim report or other filing. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-05-13 Korean
기업가치제고계획(자율공시) (2026 지구홀딩스 주식회사 기업가치 제고 계획)
Regulatory Filings Classification · 75% confidence The document is a voluntary disclosure of a corporate value enhancement plan (“기업가치 제고 계획”) outlining dividends, capital efficiency, strategic investments, governance improvements, etc. It is not an annual or interim report, earnings release, notice of dividend amount, M&A or financing transaction, board change, proxy material, or audit report. It does not present actual financial statements or detailed regulatory attestations, but rather a forward-looking plan. It thus falls under the fallback category for miscellaneous regulatory announcements that don’t fit a more specific type: Regulatory Filings (RNS).
2026-05-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.